← 홈

Antibody

12개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 12개
AntibodystaleGenentech, Inc.Phase 3

Tiragolumab (Tiragolumab)

Multiple Myeloma; Non-Hodgkin Lymphoma · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase3#인기#항체+5
효능 ORR 77.3%임상시험 64상태 ACTIVE
AntibodystaleGenmabPhase 2

Epcoritamab (Epcoritamab)

Diffuse Large B-Cell Lymphoma; Follicular Lymphoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#Antibody#Phase2#인기#항체+5
효능 ORR 0%임상시험 50상태 RECRUITING
AntibodystaleGrupo Español de Linfomas y Tra…Phase 2

Zevalin (Ibritumomab Tiuxetan, Ibritumomab Tiuxetan (Zevalin))

Non-Hodgkin Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 16%임상시험 30상태 ACTIVE
AntibodystaleADC TherapeuticsPhase 3

Loncastuximab tesirine (Loncastuximab tesirine)

Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Grade 3b Follicular Lymphoma · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#Antibody#Phase3#항체#면역항체+4
효능 ORR 94.1%임상시험 30상태 RECRUITING
AntibodystaleJohn ReneauPhase 1

Mogamulizumab (Mogamulizumab)

Recurrent Adult T-Cell Leukemia/Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma · Cutaneous T Cell Lymphoma

#CutaneousTCellLymphoma#Antibody#Phase1#항체#면역항체+5
효능 ORR 25%임상시험 30상태 RECRUITING
AntibodystaleMarcela V. Maus, M.D.,Ph.D.Phase 2

Emapalumab (Emapalumab)

Large B-cell Lymphoma; Relapsed Non-Hodgkin Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 60%임상시험 29상태 RECRUITING
AntibodystaleRegeneron PharmaceuticalsPhase 3

Odronextamab (Odronextamab)

Relapsed/Refractory Aggressive B-Cell Lymphoma · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#Antibody#Phase3#항체#면역항체+4
임상시험 18상태 RECRUITING
AntibodystaleBristol-Myers SquibbPhase 2

Lirilumab (Lirilumab)

Non-Hodgkin's Lymphoma; Hodgkin Lymphoma · Squamous Cell Carcinoma of the Head and

#SquamousCellCarcinomaoftheHeadan#Antibody#Phase2#항체#면역항체+4
효능 ORR 66.7%임상시험 13상태 ACTIVE
AntibodystaleHoffmann-La RochePhase 2

Rituxumab (Rituxumab)

B-cell Non-Hodgkin Lymphoma · B-cell Non-Hodgkin Lymphoma

#B-cellNon-HodgkinLymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 95%임상시험 4상태 ACTIVE
AntibodyBiologicstaleGenentech, Inc.Phase 2

Bispecific antibody-based combined with CAR-T cell therapy (Bispecific antibody-based combined with CAR-T cell therapy)

B-cell Non-Hodgkin Lymphoma · B-cell Non-Hodgkin Lymphoma

#B-cellNon-HodgkinLymphoma#Antibody#Phase2#항체#면역항체+2
임상시험 3상태 RECRUITING
AntibodystaleChangchun GeneScience Pharmaceu…Phase 1

Gentulizumab (Gentulizumab)

Solid Tumor; Non-Hodgkin Lymphoma · Solid Tumor

#SolidTumor#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 1

G (Obinutuzumab, Obinutuzumab (G))

B-Cell Lymphoma; Non-Hodgkin Lymphoma · B-Cell Lymphoma

#B-CellLymphoma#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 ACTIVE